ATXI vs. TRVN, MNPR, IMNN, RDHL, PIRS, KPRX, ELAB, AVTX, HUGE, and GHSI
Should you be buying Avenue Therapeutics stock or one of its competitors? The main competitors of Avenue Therapeutics include Trevena (TRVN), Monopar Therapeutics (MNPR), Imunon (IMNN), RedHill Biopharma (RDHL), Pieris Pharmaceuticals (PIRS), Kiora Pharmaceuticals (KPRX), Elevai Labs (ELAB), Avalo Therapeutics (AVTX), FSD Pharma (HUGE), and Guardion Health Sciences (GHSI). These companies are all part of the "pharmaceutical preparations" industry.
Avenue Therapeutics (NASDAQ:ATXI) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, community ranking, risk, valuation and dividends.
Avenue Therapeutics has higher earnings, but lower revenue than Trevena. Avenue Therapeutics is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.
Avenue Therapeutics has a beta of -0.09, suggesting that its stock price is 109% less volatile than the S&P 500. Comparatively, Trevena has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500.
17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 1.8% of Avenue Therapeutics shares are held by company insiders. Comparatively, 2.4% of Trevena shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Avenue Therapeutics had 12 more articles in the media than Trevena. MarketBeat recorded 14 mentions for Avenue Therapeutics and 2 mentions for Trevena. Trevena's average media sentiment score of 0.68 beat Avenue Therapeutics' score of -0.17 indicating that Trevena is being referred to more favorably in the news media.
Avenue Therapeutics' return on equity of 0.00% beat Trevena's return on equity.
Trevena has a consensus target price of $5.00, suggesting a potential upside of 1,182.05%. Given Trevena's higher probable upside, analysts plainly believe Trevena is more favorable than Avenue Therapeutics.
Trevena received 469 more outperform votes than Avenue Therapeutics when rated by MarketBeat users. Likewise, 71.79% of users gave Trevena an outperform vote while only 60.25% of users gave Avenue Therapeutics an outperform vote.
Summary
Trevena beats Avenue Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Avenue Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avenue Therapeutics Competitors List
Related Companies and Tools
